Infants

PATA and PACF have worked across 9 countries and strengthened 36 community-clinic collaborations through their partnership on the three-year C3 programme on collaboration between Clinics and Community-Based Organisations (CBOs) to deliver services together for improved PMTCT-paediatric case finding and HIV treatment.

Together, PATA and PACF have identified how clinical-CBOs collaboration at a local level can be in transforming health responses. They developed a Clinic-Community Collaboration Toolkit and accompanying Be Connected e-learning course informed by the C3 programme’s successes and lessons learnt.

Through these new tools, they hope to continue empowering health providers as well as encouraging community-based staff and local coordinators to initiate, expand and improve upon joint activities and action plans, in a collaborative effort to strengthen their work on paediatric and adolescent HIV.

Appel pour l’accélération de l’élimination de la transmission mère-enfant du VIH et le traitement antirétroviral chez l’enfant en Afrique de l’ouest et du centre d’ici 2020

Call for the acceleration of the elimination of mother-to-child HIV transmission and antiretroviral treatment for children in West and Central Africa by 2020

This implementation starter kit describes and provides access to all the materials used in the Prevention of Mother-to-Child HIV Transmission (PMTCT) component of FHI 360’s Zambia Prevention, Care and Treatment Partnership (ZPCT). The program resulted in a significant increase in the use of PMTCT services as well as significant reductions in the mother-to-child transmission of HIV among ZPCT clinic clients. It now serves as a model for other countries. This kit is designed to be used by program designers to replicate the success of the ZPCT PMTCT program in other settings. 

This diagram outlines the process to test infants exposed to HIV at birth in Cameroon.

In response to a longstanding demand for a heat-stable and easy to administer formulation of ritonavir boosted lopinavir (LPV/r) for infants and young children, a new formulation in pellet form is now available.

This fact sheet provides simplified information to facilitate proper dosing and administration of lopinavir and ritonavir 40mg/10mg oral pellets.